New depression pill shows promise in quick mood lift

NCT ID NCT06267846

Completed Symptom relief Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial tested an experimental drug called NBI-1070770 in 73 adults with major depressive disorder. Participants took the drug or a placebo for 5 days to see if it could quickly improve depression symptoms. The study is already completed, and results will show whether this approach is worth further testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NBI-1070770
What this could lead to: If successful, this could point toward a fast-acting treatment for depression that works within days.
What could go wrong: This is a small, early-phase trial (73 people) testing a short-term effect. The drug may not outperform placebo, and long-term safety and efficacy are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Neurocrine Clinical Site

Little Rock, Arkansas, 72211, United States
Neurocrine Clinical Site

Rogers, Arkansas, 72758, United States
Neurocrine Clinical Site

Lemon Grove, California, 91945, United States
Neurocrine Clinical Site

Long Beach, California, 90806, United States
Neurocrine Clinical Site

Hollywood, Florida, 33024, United States
Neurocrine Clinical Site

Maitland, Florida, 32751, United States
Neurocrine Clinical Site

Decatur, Georgia, 30030, United States
Neurocrine Clinical Site

Savannah, Georgia, 31405, United States
Neurocrine Clinical Site

Gaithersburg, Maryland, 20877, United States
Neurocrine Clinical Site

Dayton, Ohio, 45439, United States
Neurocrine Clinical Site

North Canton, Ohio, 44730, United States
Neurocrine Clinical Site

Houston, Texas, 77008, United States
Neurocrine Clinical Site

Richardson, Texas, 75080, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.